Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 9/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16491621 | 0.88 | TLR4 (0.57) | TLR4ALDH1A1LMNAPOLBHTT | |
| SCHEMBL871622 | 0.85 | TLR4 (0.50) | TLR4ALDH1A1POLBTSHRGAA | |
| SCHEMBL872380 | 0.82 | TLR4 (0.48) | TLR4ALDH1A1LMNAHTTGAA | |
| SCHEMBL1861096 | 0.79 | TLR4 (0.55) | TLR4ALDH1A1LMNAPOLBGAA | |
| SCHEMBL1860668 | 0.79 | TLR4 (0.58) | TLR4ALDH1A1LMNAPOLBHTT | |
| SCHEMBL872382 | 0.79 | TLR4 (0.60) | TLR4ALDH1A1GAA | |
| SCHEMBL871427 | 0.79 | TLR4 (0.62) | TLR4ALDH1A1POLBTSHRCA1 | |
| SCHEMBL16489094 | 0.78 | TLR4 (0.45) | TLR4ALDH1A1LMNATSHRRAB9A | |
| SCHEMBL8746923 | 0.78 | TLR4 (0.47) | TLR4ALDH1A1TSHRRAB9ACA1 | |
| SCHEMBL871297 | 0.78 | TLR4 (0.68) | TLR4HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077856-A1 | PHARMACEUTICAL PRODUCT | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-03-29 | — | — | US | disclosed |
| US-20090105314-A1 | Pharmaceutical Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-04-23 | — | — | US | disclosed |
| US-20090062355-A1 | Pharmaceutical Product | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105314-A1 | Pharmaceutical Agent | TLR1, TLR6, TPMT | TLR4 8/4885ALDH1A1 922/4885LMNA 4456/4885 |
| US-20090062355-A1 | Pharmaceutical Product | ATF1, ATF4, TLR8 | TLR4 13/4885ALDH1A1 939/4885LMNA 4365/4885 |
| US-20120077856-A1 | PHARMACEUTICAL PRODUCT | ATF1, ATF4, TLR8 | TLR4 13/4885ALDH1A1 939/4885LMNA 4365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.